Tamsulosin Hydrochloride
Product Images NDC 66116-435

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 66116-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin Hydrochloride Structural Formula (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 01)

Chemical structure of Tamsulosin Hydrochloride showing its molecular composition with labeled functional groups and HCl salt form.*

FDA Label Image

Figure 1: Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules, 0.4 mg Under Fasted And Fed Conditions (n = 8) (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 02)

A pharmacokinetic plasma concentration versus time curve comparing tamsulosin hydrochloride levels in fed and fasted states. The graph shows plasma concentration in ng/mL on the y-axis and time in hours on the x-axis, illustrating how food intake affects absorption over a 36-hour period.*

FDA Label Image

Figure 2a: Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 03)

A line graph showing the mean change over the duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.8 mg, 0.4 mg, and placebo. The x-axis represents treatment duration in weeks up to 13, and the y-axis shows the mean change values. Different markers distinguish the three groups, illustrating trends in response over time.*

FDA Label Image

Figure 2b: Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 04)

A line graph comparing mean change over treatment duration in weeks for Tamsulosin Hydrochloride at 0.4 mg and 0.8 mg doses versus placebo. The graph shows the progression across approximately 13 weeks, with separate lines representing each group and annotations for sample sizes at different time points.*

FDA Label Image

Figure 3a: Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 05)

A line graph showing mean change in mL/sec over duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.8 mg, 0.4 mg, and placebo. The x-axis represents treatment duration from baseline to about 13 weeks and LOCF, while the y-axis represents mean change in mL/sec. Data points for each group are marked with different symbols and tracked over time.*

FDA Label Image

Figure 3b: Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 06)

A line graph showing mean change in a variable (mL/sec) over duration of treatment in weeks. The graph compares effects of Tamsulosin Hydrochloride doses 0.4 mg, 0.8 mg, and placebo, depicting sample sizes at each time point.*

FDA Label Image

Tamsulosin HCl 0.4mg Capsules #30 (Cf8f5d60 A2f8 4fa4 Ba39 6d175cf3abce 07)

Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg by MedStart CONNECT, containing 30 capsules. The label includes storage instructions to keep at 20°-25°C (68°-77°F) and warnings to keep the container tightly closed and out of reach of children. Manufacturer is Teva Pharm. Ind. Ltd., Jerusalem, Israel, with distribution by Teva Pharmaceuticals USA. The label also features a phone number for free shipping and home delivery.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.